Background — According to the data from the published sources worldwide, about 10% of the world population suffers from osteoarthrosis. While searching for novel methods of osteoarthrosis treatment, we proposed administering intra-articular injections of autologous platelet-rich plasma.
The goal of this clinical study was to evaluate the effectiveness of autologous platelet-rich plasma injections in osteoarthrosis patient treatment.
Methods — This open-label parallel-group study was a pilot randomized controlled trial. An analysis of the treatment outcomes for 128 patients with knee joint arthrosis was performed. All patients were split among three groups, and subjects in two of those were receiving conventional treatment. Clinical efficacy was calculated from pain intensity, determined using Visual Analog Scale, Lequesne index and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Inflammatory response intensity was assessed by superoxide dismutase content and erythrocyte catalase activity.
Results — It was demonstrated that administering platelet-rich plasma allowed achieving tangible clinical and laboratory results without any side effects and with very few contraindications. The latter included, for instance, blocking inflammatory process in the joints, thereby inhibiting the oxidative stress, which is the most pathogenetically substantiated treatment of osteoarthrosis.
Conclusion — Thus, we have discovered that platelet-rich plasma injections had apparent anti-inflammatory and pain-relieving effects, along with inhibiting action of destructive processes in the cartilaginous tissue, hence improving life quality of the patients with osteoarthrosis.